Skip to main content
. 2018 May 2;19:266. doi: 10.1186/s13063-018-2637-0

Fig. 1.

Fig. 1

Flow of participants through the study. Any reasons for discontinuation or exclusion from analysis are reported. ET (Endurance exercise + tocilizumab), EP (Endurance exercise + saline (placebo)), RP (Resistance exercise + saline), NT (No-exercise control + tocilizumab), NP (No-exercise control + saline)